PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Colistimethate sodium - Cystic fibrosis

PAD Profile : Colistimethate sodium - Cystic fibrosis

Keywords :
NICE
Brand Names Include :
Colistin, Colomycin, Promixin

Traffic Light Status

Status 1 of 1.

Status :
Red
Important
Formulations :
  • Inhalation
Important Information :
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
01 May 2013
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Implementation of NICE TA276 - No action required Colistimethate for Cystic Fibrosis is funded by NHS England from 1st April 2013
01 April 2013
Not Set
FOR NEW PATIENTS ONLY. Prescribing of Colistimethate Sodium will be considered RED on the Prescribing Advisory database. Historically amber for CF patients via nebulisation / inhalation. GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

Associated BNF Codes

05. Infections
05.01.07. Some other antibacterials
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More